Arghavan Zebardast
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Arghavan Zebardast has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Tayebeh Latifi
Department of Virology, School of Public Health Tehran University of Medical Sciences Tehran Iran
3 shared publications Adel Abedi
Affiliation Mathematics Department, Shahid Beheshti University, Tehran, Iran
2 shared publicationsAhmad Nejati
Affiliation Virology Department, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
2 shared publicationsMehdi Shabani
Affiliation Virology Department, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
2 shared publicationsMohammad Hossein Najmi
Affiliation Faculty of Biological Sciences, Department of Bioinformatics, Tarbiat Modares University, Tehran, Iran
2 shared publications- Nazanin Zahra Shafiei-Jandaghi
Virology Department, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
2 shared publications
Latest Publications
- Open Access
- 25 June 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (6) , e0324601
A targeted approach for multiplex detection of respiratory viruses in cases with severe acute respiratory infections by nanopore sequencing
Severe acute respiratory infection (SARI) remains one of the leading causes of morbidity and mortality worldwide. Multiple viruses can cause this infection. Sequencing technologies hold great promise for detecting viral pathogens. This proof-of-concept study aimed to develop and validate a new method for multiplex detection and typing of SARI-related viruses (SARS-CoV-2, Influenza A (H1N1, H3N2), Influenza B, human respiratory syncytial virus, human adenoviruses, human enteroviruses, and human parainfluenza viruses) using a nanopore next-generation sequencing method. Following genome extraction from oropharyngeal swab samples and conventional RT-PCR assays, the libraries were barcoded and sequenced by the MinION device. The sensitivity and specificity were assessed using various serial dilutions of samples and different primer pools, respectively. Data analysis was carried out using bioinformatic tools. Finally, the protocol was validated with known positive samples. All participants provided written informed consent. During 12 hours of MinION sequencing, 711,000 reads passed the quality filters (Q-score>7). Eleven out of 12 target genes were successfully identified in clinical samples, with more than 90% coverage for most viruses. All viruses were detected by a Q30 value of more than 1%. The detection limit was measured for SARS-CoV-2, Influenza A (H1N1, H3N2), Influenza B, and human respiratory syncytial virus. The method showed 99.9% specificity in detection and was validated by 20 clinical samples. This study developed and validated a novel multiplex detection approach of Oxford Nanopore Technologies that allowed the identification of SARI-related respiratory viruses in a clinical laboratory setting.
- 25 June 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (6) , e0324601
Open AccessA targeted approach for multiplex detection of respiratory viruses in cases with severe acute respiratory infections by nanopore sequencing
Severe acute respiratory infection (SARI) remains one of the leading causes of morbidity and mortality worldwide. Multiple viruses can cause this infection. Sequencing technologies hold great promise for detecting viral pathogens. This proof-of-concept study aimed to develop and validate a new method for multiplex detection and typing of SARI-related viruses (SARS-CoV-2, Influenza A (H1N1, H3N2), Influenza B, human respiratory syncytial virus, human adenoviruses, human enteroviruses, and human parainfluenza viruses) using a nanopore next-generation sequencing method. Following genome extraction from oropharyngeal swab samples and conventional RT-PCR assays, the libraries were barcoded and sequenced by the MinION device. The sensitivity and specificity were assessed using various serial dilutions of samples and different primer pools, respectively. Data analysis was carried out using bioinformatic tools. Finally, the protocol was validated with known positive samples. All participants provided written informed consent. During 12 hours of MinION sequencing, 711,000 reads passed the quality filters (Q-score>7). Eleven out of 12 target genes were successfully identified in clinical samples, with more than 90% coverage for most viruses. All viruses were detected by a Q30 value of more than 1%. The detection limit was measured for SARS-CoV-2, Influenza A (H1N1, H3N2), Influenza B, and human respiratory syncytial virus. The method showed 99.9% specificity in detection and was validated by 20 clinical samples. This study developed and validated a novel multiplex detection approach of Oxford Nanopore Technologies that allowed the identification of SARI-related respiratory viruses in a clinical laboratory setting.
- Open Access
- 1 September 2024
- Published by Wiley
Development of multiplex nanopore sequencing method for the detection of multiple respiratory viruses in cases with severe acute respiratory infections
Background: Severe acute respiratory infection (SARI) remains one of the leading causes of morbidity and mortality worldwide. Multiple respiratory viral pathogens can cause this infection. Sequencing technologies hold great promise for detecting viral pathogens. This study aimed to develop and validate a method for the multiplex detection of SARI-related viruses (SARS-CoV-2, Influenza A (H1N1, H3N2), Influenza B, human respiratory syncytial virus, human adenoviruses, human enteroviruses, and human parainfluenza viruses) using a nanopore next-generation sequencing method. Methods: Following genome extraction from oropharyngeal swab samples and conventional RT-PCR assays, the libraries were barcoded and sequenced by the MinION flow cell. The sensitivity and specificity were assessed using various serial dilutions of samples and different primer pools, respectively. NGS data analysis, including adaptor trimming, assembly, mapping, and the generation of consensus sequences, was carried out using bioinformatic tools. Finally, the protocol was validated by evaluating with known positive samples. Results: During 12 hours of MinION sequencing, 711,000 reads passed the quality filters (Q-score>7). 11 out of 12 target genes were successfully identified in clinical samples, with more than 90% coverage for most viruses. All the viruses detected by Q30 value of more than 1%. The detection limit was measured for SARS-CoV-2, Influenza A (H1N1, H3N2), Influenza B, and human respiratory syncytial virus. The platform showed 99.9% specificity in detection and was validated by 20 clinical samples. Conclusion: This study developed and validated a novel multiplex detection method that made it possible to identify SARI-related respiratory viruses in a clinical laboratory setting.
- 1 September 2024
- Published by Wiley
Open AccessDevelopment of multiplex nanopore sequencing method for the detection of multiple respiratory viruses in cases with severe acute respiratory infections
Background: Severe acute respiratory infection (SARI) remains one of the leading causes of morbidity and mortality worldwide. Multiple respiratory viral pathogens can cause this infection. Sequencing technologies hold great promise for detecting viral pathogens. This study aimed to develop and validate a method for the multiplex detection of SARI-related viruses (SARS-CoV-2, Influenza A (H1N1, H3N2), Influenza B, human respiratory syncytial virus, human adenoviruses, human enteroviruses, and human parainfluenza viruses) using a nanopore next-generation sequencing method. Methods: Following genome extraction from oropharyngeal swab samples and conventional RT-PCR assays, the libraries were barcoded and sequenced by the MinION flow cell. The sensitivity and specificity were assessed using various serial dilutions of samples and different primer pools, respectively. NGS data analysis, including adaptor trimming, assembly, mapping, and the generation of consensus sequences, was carried out using bioinformatic tools. Finally, the protocol was validated by evaluating with known positive samples. Results: During 12 hours of MinION sequencing, 711,000 reads passed the quality filters (Q-score>7). 11 out of 12 target genes were successfully identified in clinical samples, with more than 90% coverage for most viruses. All the viruses detected by Q30 value of more than 1%. The detection limit was measured for SARS-CoV-2, Influenza A (H1N1, H3N2), Influenza B, and human respiratory syncytial virus. The platform showed 99.9% specificity in detection and was validated by 20 clinical samples. Conclusion: This study developed and validated a novel multiplex detection method that made it possible to identify SARI-related respiratory viruses in a clinical laboratory setting.
- Open Access
- 23 August 2024
- Published by Springer Nature in Virology Journal
- Vol. 21 (1) , 1-17
From discovery to treatment: tracing the path of hepatitis E virus
The hepatitis E virus (HEV) is a major cause of acute viral hepatitis worldwide. HEV is classified into eight genotypes, labeled HEV-1 through HEV-8. Genotypes 1 and 2 exclusively infect humans, while genotypes 3, 4, and 7 can infect both humans and animals. In contrast, genotypes 5, 6, and 8 are restricted to infecting animals. While most individuals with a strong immune system experience a self-limiting infection, those who are immunosuppressed may develop chronic hepatitis. Pregnant women are particularly vulnerable to severe illness and mortality due to HEV infection. In addition to liver-related complications, HEV can also cause extrahepatic manifestations, including neurological disorders. The immune response is vital in determining the outcome of HEV infection. Deficiencies in T cells, NK cells, and antibody responses are linked to poor prognosis. Interestingly, HEV itself contains microRNAs that regulate its replication and modify the host’s antiviral response. Diagnosis of HEV infection involves the detection of HEV RNA and anti-HEV IgM/IgG antibodies. Supportive care is the mainstay of treatment for acute infection, while chronic HEV infection may be cleared with the use of ribavirin and pegylated interferon. Prevention remains the best approach against HEV, focusing on sanitation infrastructure improvements and vaccination, with one vaccine already licensed in China. This comprehensive review provides insights into the spread, genotypes, prevalence, and clinical effects of HEV. Furthermore, it emphasizes the need for further research and attention to HEV, particularly in cases of acute hepatitis, especially among solid-organ transplant recipients.
- 23 August 2024
- Published by Springer Nature in Virology Journal
- Vol. 21 (1) , 1-17
Open AccessFrom discovery to treatment: tracing the path of hepatitis E virus
The hepatitis E virus (HEV) is a major cause of acute viral hepatitis worldwide. HEV is classified into eight genotypes, labeled HEV-1 through HEV-8. Genotypes 1 and 2 exclusively infect humans, while genotypes 3, 4, and 7 can infect both humans and animals. In contrast, genotypes 5, 6, and 8 are restricted to infecting animals. While most individuals with a strong immune system experience a self-limiting infection, those who are immunosuppressed may develop chronic hepatitis. Pregnant women are particularly vulnerable to severe illness and mortality due to HEV infection. In addition to liver-related complications, HEV can also cause extrahepatic manifestations, including neurological disorders. The immune response is vital in determining the outcome of HEV infection. Deficiencies in T cells, NK cells, and antibody responses are linked to poor prognosis. Interestingly, HEV itself contains microRNAs that regulate its replication and modify the host’s antiviral response. Diagnosis of HEV infection involves the detection of HEV RNA and anti-HEV IgM/IgG antibodies. Supportive care is the mainstay of treatment for acute infection, while chronic HEV infection may be cleared with the use of ribavirin and pegylated interferon. Prevention remains the best approach against HEV, focusing on sanitation infrastructure improvements and vaccination, with one vaccine already licensed in China. This comprehensive review provides insights into the spread, genotypes, prevalence, and clinical effects of HEV. Furthermore, it emphasizes the need for further research and attention to HEV, particularly in cases of acute hepatitis, especially among solid-organ transplant recipients.
- 5 February 2023
- Published by Wiley in Cell Biology International
- Vol. 47 (5) , 848-858
COVID‐19: A trigger of autoimmune diseases
The SARS‐coronavirus‐2 (SARS‐CoV‐2) that causes coronavirus disease 2019 (COVID‐19), has spread worldwide and caused a global health emergency. SARS‐CoV‐2 is a coronaviridae virus that infects target cells by interacting with the plasma membrane‐expressed angiotensin‐converting enzyme 2 (ACE2) via the S1 component of the S protein. Effective host immune response to SARS‐CoV‐2 infection, which includes both innate and adaptive immunity, is critical for virus management and elimination. The intensity and outcome of COVID‐19 may be related to an overabundance of pro‐inflammatory cytokines, which results in a “cytokine storm” and acute respiratory distress syndrome. After SARS‐CoV‐2 infection, the immune system's hyperactivity and production of autoantibodies may result in autoimmune diseases such as autoimmune hemolytic anemia, autoimmune thrombocytopenia, Guillain‐Barré syndrome, vasculitis, multiple sclerosis, pro‐thrombotic state, and diffuse coagulopathy, as well as certain autoinflammatory conditions such as Kawasaki disease in children. We have reviewed the association between COVID‐19 and autoimmune disorders in this article.
- 5 February 2023
- Published by Wiley in Cell Biology International
- Vol. 47 (5) , 848-858
COVID‐19: A trigger of autoimmune diseases
The SARS‐coronavirus‐2 (SARS‐CoV‐2) that causes coronavirus disease 2019 (COVID‐19), has spread worldwide and caused a global health emergency. SARS‐CoV‐2 is a coronaviridae virus that infects target cells by interacting with the plasma membrane‐expressed angiotensin‐converting enzyme 2 (ACE2) via the S1 component of the S protein. Effective host immune response to SARS‐CoV‐2 infection, which includes both innate and adaptive immunity, is critical for virus management and elimination. The intensity and outcome of COVID‐19 may be related to an overabundance of pro‐inflammatory cytokines, which results in a “cytokine storm” and acute respiratory distress syndrome. After SARS‐CoV‐2 infection, the immune system's hyperactivity and production of autoantibodies may result in autoimmune diseases such as autoimmune hemolytic anemia, autoimmune thrombocytopenia, Guillain‐Barré syndrome, vasculitis, multiple sclerosis, pro‐thrombotic state, and diffuse coagulopathy, as well as certain autoinflammatory conditions such as Kawasaki disease in children. We have reviewed the association between COVID‐19 and autoimmune disorders in this article.
- 14 October 2021
- Published by Springer Nature in Molecular Biology Reports
- Vol. 49 (1) , 647-656
The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization
The severe acute respiratory syndrome (SARS-CoV-2), a newly emerging of coronavirus, continues to infect humans in the absence of a viable treatment. Neutralizing antibodies that disrupt the interaction of RBD and ACE2 has been under the spotlight as a way of developing the COVID-19 treatment. Some animals, such as llamas, manufacture heavy-chain antibodies that have a single variable domain (VHH) instead of two variable domains (VH/VL) as opposed to typical antibodies. Nanobodies are antigen-specific, single-domain, changeable segments of camelid heavy chain-only antibodies that are recombinantly produced. These types of antibodies exhibit a wide range of strong physical and chemical properties, like high solubility, and stability. The VHH's high-affinity attachment to the receptor-binding domain (RBD) allowed the neutralization of SARS-CoV-2. To tackle COVID-19, some nanobodies are being developed against SARS-CoV-2, some of which have been recently included in clinical trials. Nanobody therapy may be useful in managing the COVID-19 pandemic as a potent and low-cost treatment. This paper describes the application of nanobodies as a new class of recombinant antibodies in COVID-19 treatment.
- 14 October 2021
- Published by Springer Nature in Molecular Biology Reports
- Vol. 49 (1) , 647-656
The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization
The severe acute respiratory syndrome (SARS-CoV-2), a newly emerging of coronavirus, continues to infect humans in the absence of a viable treatment. Neutralizing antibodies that disrupt the interaction of RBD and ACE2 has been under the spotlight as a way of developing the COVID-19 treatment. Some animals, such as llamas, manufacture heavy-chain antibodies that have a single variable domain (VHH) instead of two variable domains (VH/VL) as opposed to typical antibodies. Nanobodies are antigen-specific, single-domain, changeable segments of camelid heavy chain-only antibodies that are recombinantly produced. These types of antibodies exhibit a wide range of strong physical and chemical properties, like high solubility, and stability. The VHH's high-affinity attachment to the receptor-binding domain (RBD) allowed the neutralization of SARS-CoV-2. To tackle COVID-19, some nanobodies are being developed against SARS-CoV-2, some of which have been recently included in clinical trials. Nanobody therapy may be useful in managing the COVID-19 pandemic as a potent and low-cost treatment. This paper describes the application of nanobodies as a new class of recombinant antibodies in COVID-19 treatment.
- 28 January 2021
- Published by Wiley in Journal of Cellular Physiology
- Vol. 236 (9) , 6136-6153
Critical review of Epstein–Barr virus microRNAs relation with EBV‐associated gastric cancer
Epstein–Barr virus (EBV)‐associated gastric cancer (EBVaGC) is regarded as the most prevalent malignant tumor triggered by EBV infection. In recent years, increasing attention has been considered to recognize more about the disease process's exact mechanisms. There is accumulating evidence that showing epigenetic modifications play critical roles in the EBVaGC pathogenesis. MicroRNAs (miRNAs), as critical epigenetic modulators, are single‐strand short noncoding RNA (length ~ <200 bp), which regulate gene expression through binding to the 3ʹ‐untranslated region (3ʹ‐UTR) of target RNA transcripts and either degrade or repress their activities. In the latest research on EBV, it was found that this virus could encode miRNAs. Mechanistically, EBV‐encoded miRNAs are involved in carcinogenesis and the progression of EBV‐associated malignancies. Moreover, these miRNAs implicated in immune evasion, identification of pattern recognition receptors, regulation of lymphocyte activation and lethality, modulation of infected host cell antigen, maintain of EBV infection status, promotion of cell proliferation, invasion and migration, and reduction of apoptosis. As good news, not only has recent data demonstrated the crucial function of EBV‐encoded miRNAs in the pathogenesis of EBVaGC, but it has also been revealed that aberrant expression of exosomal miRNAs in EBVaGC has made them biomarkers for detection of EBVaGC. Regarding these substantial characterizes, the critical role of EBV‐encoded miRNAs has been a hot topic in research. In this review, we will focus on the multiple mechanisms involved in EBVaGC caused by EBV‐encoded miRNAs and briefly discuss their potential application in the clinic as a diagnostic biomarker.
- 28 January 2021
- Published by Wiley in Journal of Cellular Physiology
- Vol. 236 (9) , 6136-6153
Critical review of Epstein–Barr virus microRNAs relation with EBV‐associated gastric cancer
Epstein–Barr virus (EBV)‐associated gastric cancer (EBVaGC) is regarded as the most prevalent malignant tumor triggered by EBV infection. In recent years, increasing attention has been considered to recognize more about the disease process's exact mechanisms. There is accumulating evidence that showing epigenetic modifications play critical roles in the EBVaGC pathogenesis. MicroRNAs (miRNAs), as critical epigenetic modulators, are single‐strand short noncoding RNA (length ~ <200 bp), which regulate gene expression through binding to the 3ʹ‐untranslated region (3ʹ‐UTR) of target RNA transcripts and either degrade or repress their activities. In the latest research on EBV, it was found that this virus could encode miRNAs. Mechanistically, EBV‐encoded miRNAs are involved in carcinogenesis and the progression of EBV‐associated malignancies. Moreover, these miRNAs implicated in immune evasion, identification of pattern recognition receptors, regulation of lymphocyte activation and lethality, modulation of infected host cell antigen, maintain of EBV infection status, promotion of cell proliferation, invasion and migration, and reduction of apoptosis. As good news, not only has recent data demonstrated the crucial function of EBV‐encoded miRNAs in the pathogenesis of EBVaGC, but it has also been revealed that aberrant expression of exosomal miRNAs in EBVaGC has made them biomarkers for detection of EBVaGC. Regarding these substantial characterizes, the critical role of EBV‐encoded miRNAs has been a hot topic in research. In this review, we will focus on the multiple mechanisms involved in EBVaGC caused by EBV‐encoded miRNAs and briefly discuss their potential application in the clinic as a diagnostic biomarker.